CLINICAL CHARACTERISTICS, TREATMENT PATTERNS AND HEALTH CARE UTILIZATION IN ER+/HER2-METASTATIC POSTMENOPAUSAL BREAST CANCER PATIENTS: RESULTS FROM A RETROSPECTIVE MEDICAL RECORD REVIEW IN THE UNITED STATES

被引：0
|
作者：
Zanotti, G. [1 ]
Hunger, M. [2 ]
Perkins, J. J. [1 ]
Horblyuk, R. [1 ]
Martin, M. [3 ]
机构：
[1] Pfizer Inc, New York, NY USA
[2] Mapi Grp, Munich, Germany
[3] Mapi Grp, Uxbridge, Middx, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1646
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN24
引用
收藏
页码：A137 / A138
页数：2
相关论文
共 50 条
  • [21] Real-world patient characteristics, utilization patterns, and outcomes of US patients with HR+/HER2-metastatic breast cancer treated with abemaciclib
    Saverno, Kimberly R.
    Beyrer, Julie
    Smyth, Emily Nash
    Abedtash, Hamad
    DeLuca, Angelo
    Zhu, Yajun Emily
    Rybowski, Sarah
    CANCER RESEARCH, 2021, 81 (04)
  • [22] Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2-Metastatic Breast Cancer Treated with Abemaciclib
    Smyth, Emily Nash
    Beyrer, Julie
    Saverno, Kimberly R.
    Hadden, Elizabeth
    Abedtash, Hamed
    DeLuca, Angelo
    Lawrence, Garreth W.
    Rybowski, Sarah
    DRUGS-REAL WORLD OUTCOMES, 2022, 9 (04) : 681 - 693
  • [23] Real-world treatment patterns, healthcare resource utilization and costs of care among newly-diagnosed patients with HR+/HER2-metastatic breast cancer
    Basho, Reva K.
    Ng, Carmen
    Dillon, Allison
    Chen, Lu
    Cheng, Anna
    Du Toit, Yolande
    Abbass, Ibrahim M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] CLINICAL CHARACTERISTICS, TREATMENT PATTERNS, AND HEALTH CARE RESOURCE UTILIZATION IN UNRESECTABLE, LOCALLY ADVANCED, STAGE III NON-SMALL CELL LUNG CANCER: A MEDICAL RECORD REVIEW STUDY IN THE UNITED STATES AND CANADA
    Kurosky, S.
    Klein, A. B.
    Parikh, R. C.
    Trantham, L.
    Zhang, Y.
    Levine, C. A.
    Kaye, J. A.
    VALUE IN HEALTH, 2018, 21 : S49 - S49
  • [25] Impact of adding palbociclib to letrozole on pain severity and pain interference with various activities of daily life in patients with ER+, HER2-metastatic breast cancer as first line treatment
    Bell, Timothy
    Crown, John Paul
    Lang, Istvan
    Bhattacharyya, Helen
    Zanotti, Giovanni
    Randolph, Sophia
    Kim, Sindy
    Huang, Xin
    Bartlett, Cynthia Huang
    Finn, Richard
    Slamon, Dennis
    CANCER RESEARCH, 2015, 75
  • [26] Results of a retrospective study on the efficacy and safety of alpelisib in patients with HR+/HER2-metastatic breast cancer in real-world clinical practice
    Sultanbaev, Alexander Valerievich
    Kolyadina, Irina Vladimirovna
    Menshikov, Konstantin
    Musin, Shamil
    Sultanbaeva, Nadezda
    Lipatov, Danila
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Combination of hormone therapy, GnRH agonist, and immunotherapy enhance immune activation in premenopausal ER+/HER2-metastatic breast cancer patients: Results of biomarker analysis from a pilot phase II study
    Chen, I-Chun
    Lin, Ching-Hung
    Chang, Dwan-Ying
    Chen, Tom Wei-Wu
    Wang, Ming-Yang
    Ma, Wei-Li
    Lin, Yi-Ting
    Huang, Shu-Min
    Lu, Yen-Shen
    CANCER RESEARCH, 2023, 83 (08)
  • [28] EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2-metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
    Bardia, Aditya
    Bidard, Francois-Clement
    Neven, Patrick
    Streich, Guillermo
    Montero, Alberto J.
    Forget, Frederic
    Mouret-Reynier, Marie-Ange
    Sohn, Joo Hyuk
    Taylor, Donatienne
    Harnden, Kathleen K.
    Khong, Hung
    Kocsis, Judit
    Dalenc, Florence
    Dillon, Patrick
    Babu, Sunil
    Waters, Simon
    Deleu, Ines
    Garcia-Saenz, Jose Angel
    Bria, Emilio
    Cazzaniga, Marina Elena
    Aftimos, Philippe
    Cortes, Javier
    Tonini, Giulia
    Sahmoud, Tarek
    Habboubi, Nassir
    Grzegorzewski, Krzysztof
    Kaklamani, Virginia
    CANCER RESEARCH, 2023, 83 (05)
  • [29] Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study
    Athanasios Kotsakis
    Alexandros Ardavanis
    Georgios Koumakis
    Epameinondas Samantas
    Amanta Psyrri
    Christos Papadimitriou
    BMC Cancer, 19
  • [30] Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study
    Kotsakis, Athanasios
    Ardavanis, Alexandros
    Koumakis, Georgios
    Samantas, Epameinondas
    Psyrri, Amanta
    Papadimitriou, Christos
    BMC CANCER, 2019, 19 (1)
12345